Aarti Pharmalabs Limited (AARTIPHARM) Financial History

Name: Aarti Pharmalabs Limited (AARTIPHARM) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Aarti Pharmalabs Limited (AARTIPHARM) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 2,421 employees. Its market capitalization is roughly ₹74 billion. In the fiscal year ended 2026-03-31, AARTIPHARM reported ₹17.9B in revenue and ₹1.7B in net income.

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally.

Interactive charts & full statements →

AARTIPHARM Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹17.9B	₹20.9B	₹18.2B	₹19.4B	—
Gross Profit	₹7.9B	₹8.7B	₹7.0B	₹6.8B	—
Operating Income (EBIT)	₹3.0B	₹3.8B	₹3.1B	₹2.8B	—
Net Income	₹1.7B	₹2.7B	₹2.2B	₹1.9B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AARTIPHARM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹5.4B	₹5.8B	₹4.3B	₹4.2B	₹3.9B
Gross Profit	₹3.0B	₹3.0B	₹2.6B	₹2.1B	₹2.2B
Operating Income (EBIT)	₹1.0B	₹1.0B	₹737M	₹500M	₹724M
Net Income	₹761M	₹611M	₹480M	₹279M	₹460M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AARTIPHARM Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹363M)	(₹317M)	(₹181M)	(₹181M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AARTIPHARM Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹34.8B	₹29.0B	₹25.8B	₹22.4B	—
Total Liabilities	₹13.6B	₹9.1B	₹8.3B	₹6.9B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AARTIPHARM viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

VIYASH · Viyash Scientific Limited — ₹110 billion
SUVEN · Suven Life Sciences Limited — ₹97 billion
PGHL · Procter & Gamble Health Limited — ₹91 billion
4559 · Zeria Pharmaceutical Co., Ltd. — JPY 89 billion
BLISSGVS · Bliss GVS Pharma Limited — ₹73 billion
INNOVACAP · Innova Captab Limited — ₹68 billion
MOREPENLAB · Morepen Laboratories Limited — ₹66 billion
4569 · KYORIN Pharmaceutical Co., Ltd. — JPY 65 billion

← AARTIIND All “A” companies AARTISURF →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.